Return to Today's science sparks archives

2016-01-04

Fig 2. Fluorescence staining of cartilage slides. a Cells with intact nuclei (DAPI, ×200).

Fig 2. Fluorescence staining of cartilage slides. a Cells with intact nuclei (DAPI, ×200).
  • Prince DE, Greisberg JK

  • J Orthop Traumatol. 2015 Dec;16(4):335-41.
Open Access button

2016-01-05

Fig 1. Five-year, recurrence-free survival (RFS) stratified by Tg level.

Fig 1. Five-year, recurrence-free survival (RFS) stratified by Tg level.
  • Ibrahimpasic T, Ghossein R, Carlson DL, Nixon IJ, Palmer FL, Patel SG, Tuttle RM, Shaha A, Shah JP, Ganly I

  • Ann Surg Oncol. 2015 Dec;22(13):4193-7.

2016-01-06

Fig 1. Immunohistochemical analyses of estrogen receptor-α (ERα) and progesterone receptor (PR) using tissue microarrays (original magnification, A–F: × 100 magnification).

Fig 1. Immunohistochemical analyses of estrogen receptor-α (ERα) and progesterone receptor (PR) using tissue microarrays (original magnification, A–F: × 100 magnification).
  • Kadota K, Eguchi T, Villena-Vargas J, Woo KM, Sima CS, Jones DR, Travis WD, Adusumilli PS

  • Oncotarget. 2015 Sep 29;6(29):27505-18.
Open Access button

2016-01-07

Fig 1. Kaplan-Meier plots showing overall (OS) and disease-specific (DSS) survival stratified by p16 status (a) and stratified by risk group category (b). p values based on log-rank test.

Fig 1. Kaplan-Meier plots showing overall (OS) and disease-specific (DSS) survival stratified by p16 status (a) and stratified by risk group category (b). p values based on log-rank test.
  • Iyer NG, Dogan S, Palmer F, Rahmati R, Nixon IJ, Lee N, Patel SG, Shah JP, Ganly I

  • Ann Surg Oncol. 2015 Dec;22(13):4411-21.

2016-01-08

Fig 7. Molecular Separation of Mouse Gliomas Based on Cell of Origin.

Fig 7. Molecular Separation of Mouse Gliomas Based on Cell of Origin.
  • Alcantara Llaguno SR, Wang Z, Sun D, Chen J, Xu J, Kim E, Hatanpaa KJ, Raisanen JM, Burns DK, Johnson JE, Parada LF

  • Can Cell. 2015 Oct; 28(4): 429-440.

2016-01-11

Fig 1. Changes in the use of thoracotomy techniques at Memorial Hospital for resection of bilateral pulmonary metastases.

Fig 1. Changes in the use of thoracotomy techniques at Memorial Hospital for resection of bilateral pulmonary metastases.
  • Downey RJ, Bains MS

  • Thorac Surg Clin. 2016 Feb;26(1):13-8.

2016-01-12

Fig 1. Mechanisms of action of immunotherapy modalities.

Fig 1. Mechanisms of action of immunotherapy modalities.
  • Batlevi CL, Matsuki E, Brentjens RJ, Younes A

  • Nat Rev Clin Oncol. 2016 Jan;13(1):25-40.

2016-01-13

Fig 3. Portal venous perfusion (top) and local function probability maps (bottom) at pre-RT (left column) and 1 month after RT (right column).

Fig 3. Portal venous perfusion (top) and local function probability maps (bottom) at pre-RT (left column) and 1 month after RT (right column).
  • Wang H, Feng M, Jackson A, Ten Haken RK, Lawrence TS, Cao Y

  • Int J Radiat Oncol Biol Phys. 2016 Jan 1;94(1):181-8.

2016-01-14

Fig 1. Spectroscopic imaging of 2HG.

Fig 1. Spectroscopic imaging of 2HG.
  • Gialleonardo VD, Wilson DM, Keshari KR

  • Semin Nucl Med. 2016 Jan;46(1):28-39.

2016-01-15

Fig 2. Myeloid development and maintenance in the mouse embryo and adult mouse.

Fig 2. Myeloid development and maintenance in the mouse embryo and adult mouse.
  • Perdiguero EG, Geissmann F

  • Nat Immunol. 2015 Dec 17;17(1):2-8.

2016-01-18

Fig 2. Efficient knockdown of Malat1 in tumors using ASOs.

Fig 2. Efficient knockdown of Malat1 in tumors using ASOs.
  • Arun G, Diermeier S, Akerman M, Chang KC, Wilkinson JE, Hearn S, Kim Y, MacLeod AR, Krainer AR, Norton L, Brogi E, Egeblad M, Spector DL

  • Genes Dev. 2016 Jan 1;30(1):34-51.

2016-01-19

Fig 1. Outline of the PROSPECT trial.

Fig 1. Outline of the PROSPECT trial.
  • Weiser MR

  • Ann Surg Oncol. 2016 Jan;23(1):12-5.

2016-01-20

Fig 1B. Clear cell renal cell carcinoma (RCC).

Fig 1B. Clear cell renal cell carcinoma (RCC).
  • Hötker AM, Mazaheri Y, Wibmer A, Zheng J, Moskowitz CS, Tickoo SK, Russo P, Hricak H, Akin O

  • AJR Am J Roentgenol. 2016 Jan;206(1):100-5.

2016-01-21

Fig 4.  In IPMNs, rupture of the ducts can lead to extrusion of mucin into the stroma, which can be difficult to distinguish from true invasive colloid carcinoma (hematoxylin and eosin stain).

Fig 4. In IPMNs, rupture of the ducts can lead to extrusion of mucin into the stroma, which can be difficult to distinguish from true invasive colloid carcinoma (hematoxylin and eosin stain).
  • Adsay V1, Mino-Kenudson M, Furukawa T, Basturk O, Zamboni G, Marchegiani G, Bassi C, Salvia R, Malleo G, Paiella S, Wolfgang CL, Matthaei H, Offerhaus GJ, Adham M, Bruno MJ, Reid MD, Krasinskas A, Klöppel G, Ohike N, Tajiri T, Jang KT, Roa JC, Allen P, Castillo CF, Jang JY, Klimstra DS, Hruban RH

  • Ann Surg. 2016 Jan;263(1):162-77.

2016-01-22

Fig 8. (A) Of the 1,616,900 clinical PET/CT and PET scans performed in 2014, 93% (1,510,800) were for oncology studies, 4% (61,500) were for cardiology studies, and 3% (42,400) were for neurology studies. A negligible 0.3% (2200) scans were other types of PET scans. (B) Of the PET scans performed in 2014, 98% were performed on adults and 2% were performed on pediatric patients. (C) In 2014, 97% of all PET scans were performed on an outpatient basis and 3% were for inpatients.

Fig 8. (A) Of the 1,616,900 clinical PET/CT and PET scans performed in 2014, 93% (1,510,800) were for oncology studies, 4% (61,500) were for cardiology studies, and 3% (42,400) were for neurology studies. A negligible 0.3% (2200) scans were other types of PET scans. (B) Of the PET scans performed in 2014, 98% were performed on adults and 2% were performed on pediatric patients. (C) In 2014, 97% of all PET scans were performed on an outpatient basis and 3% were for inpatients.
  • Arevalo-Perez J, Paris M, Graham MM, Osborne JR

  • Semin Nucl Med. 2016 Jan;46(1):88-96.

2016-01-25

Fig 3. OS from time to treatment failure of CORAL induction according to transplantation performed (yes, n=64 patients; no, n=129 patients).

Fig 3. OS from time to treatment failure of CORAL induction according to transplantation performed (yes, n=64 patients; no, n=129 patients).
  • Van Den Neste E, Schmitz N, Mounier N, Gill D, Linch D, Trneny M, Milpied N, Radford J, Ketterer N, Shpilberg O, Dührsen U, Ma D, Brière J, Thieblemont C, Salles G, Moskowitz CH, Glass B, Gisselbrecht C

  • Bone Marrow Transplant. 2016 Jan;51(1):51-7.

2016-01-27

Fig 8. Sequential Notch ligand–receptor activation during ventricular chamber development.

Fig 8. Sequential Notch ligand–receptor activation during ventricular chamber development.
  • D'Amato G, Luxán G, Del Monte-Nieto G, Martínez-Poveda B, Torroja C, Walter W, Bochter MS, Benedito R, Cole S, Martinez F, Hadjantonakis AK, Uemura A, Jiménez-Borreguero LJ, de la Pompa JL

  • Nat Cell Biol. 2016 Jan;18(1):7-20.

2016-01-28

Fig 1A. 45-year-old woman with multifocal nonenhancing glioma.

Fig 1A. 45-year-old woman with multifocal nonenhancing glioma.
  • Rosenkrantz AB, Friedman K, Chandarana H, Melsaether A, Moy L, Ding YS, Jhaveri K, Beltran L, Jain R

  • AJR Am J Roentgenol. 2016 Jan;206(1):162-72.

2016-01-29

Fig 1. TPO-Cre/FR-HrasG12V/Nf2flox2 mice develop poorly differentiated thyroid cancers with strong activation of MAPK signaling.

Fig 1. TPO-Cre/FR-HrasG12V/Nf2flox2 mice develop poorly differentiated thyroid cancers with strong activation of MAPK signaling.
  • Garcia-Rendueles ME, Ricarte-Filho JC, Untch BR, Landa I, Knauf JA, Voza F, Smith VE, Ganly I, Taylor BS, Persaud Y, Oler G, Fang Y, Jhanwar SC, Viale A, Heguy A, Huberman KH, Giancotti F, Ghossein R, Fagin JA

  • Cancer Discov. 2015 Nov;5(11):1178-93.

2016-02-01

Fig 1. Somatic mutations associated with acute myeloid leukemia.

Fig 1. Somatic mutations associated with acute myeloid leukemia.
  • Komanduri KV, Levine RL

  • Annu Rev Med. 2016 Jan 14;67:59-72.

2016-02-02

Fig 1. Word cloud created from free text: “Please reflect on your experience performing asylum evaluations”.

Fig 1. Word cloud created from free text: “Please reflect on your experience performing asylum evaluations”.
  • Mishori R, Hannaford A, Mujawar I, Ferdowsian H, Kureshi S

  • J Immigr Minor Health. 2016 Feb;18(1):210-8.

2016-02-03

Fig 1. Representation of the 14 most frequently altered genes in a series of 82 upper tract urothelial carcinoma tumors.

Fig 1. Representation of the 14 most frequently altered genes in a series of 82 upper tract urothelial carcinoma tumors.
  • Li Q, Bagrodia A, Cha EK, Coleman JA

  • Curr Urol Rep. 2016 Feb;17(2):12.

2016-02-04

Fig 1. Pathologic T staging.

Fig 1. Pathologic T staging.
  • Clemens MW, Medeiros LJ, Butler CE, Hunt KK, Fanale MA, Horwitz S, Weisenburger DD, Liu J, Morgan EA, Kanagal-Shamanna R, Parkash V, Ning J, Sohani AR, Ferry JA, Mehta-Shah N, Dogan A, Liu H, Thormann N, DiNapoli A, Lade S, Piccolini J, Reyes R, Williams T, McCarthy CM, Hanson SE, Nastoupil LJ, Gaur R, Oki Y, Young KH, Miranda RN

  • J Clin Oncol. 2016 Jan 10;34(2):160-8.

2016-02-05

Fig 2. Validation of Chromatin Data and Sensitivity to Low-Input Samples.

Fig 2. Validation of Chromatin Data and Sensitivity to Low-Input Samples.
  • van Galen P, Viny AD, Ram O, Ryan RJ, Cotton MJ, Donohue L, Sievers C, Drier Y, Liau BB, Gillespie SM, Carroll KM, Cross MB, Levine RL, Bernstein BE

  • Mol Cell. 2016 Jan 7;61(1):170-80.

2016-02-08

Fig 2. Confocal microscopy of HeLa proteolipobeads.

Fig 2. Confocal microscopy of HeLa proteolipobeads.
  • Gilchrist ML, Ahn K, Li YM

  • Anal Chem. 2016 Jan 19;88(2):1303-11.

2016-02-09

Fig 1. Metastatic colonization.

Fig 1. Metastatic colonization.
  • Massagué J, Obenauf AC

  • Nature. 2016 Jan 21;529(7586):298-306.

2016-02-10

Venetoclax Schedules, Pharmacokinetic Response, and Activity against Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL).

Venetoclax Schedules, Pharmacokinetic Response, and Activity against Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL).
  • Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, Kipps TJ, Anderson MA, Brown JR, Gressick L, Wong S, Dunbar M, Zhu M, Desai MB, Cerri E, Heitner Enschede S, Humerickhouse RA, Wierda WG, Seymour JF

  • N Engl J Med. 2016 Jan 28;374(4):311-22.

2016-02-11

Fig 4. Method to determine the Ki67 index.

Fig 4. Method to determine the Ki67 index.
  • Klimstra DS

  • Hematol Oncol Clin North Am. 2016 Feb;30(1):1-19.

2016-02-12

Fig 1. A comprehensive profile of the genomic alterations in LMS and associated clinical information with samples sorted by location of tumor.

Fig 1. A comprehensive profile of the genomic alterations in LMS and associated clinical information with samples sorted by location of tumor.
  • Agaram NP, Zhang L, LeLoarer F, Silk T, Sung YS, Scott SN, Kuk D, Qin LX, Berger MF, Antonescu CR, Singer S

  • Genes Chromosomes Cancer. 2016 Feb;55(2):124-30.

2016-02-15

Fig 3. Covariance matrix of radiomic features.

Fig 3. Covariance matrix of radiomic features.
  • Gillies RJ, Kinahan PE, Hricak H

  • Radiology. 2016 Feb;278(2):563-77.

2016-02-16

Fig 1. Histologic appearance of bronchial carcinoid tumors.

Fig 1. Histologic appearance of bronchial carcinoid tumors.
  • Litvak A, Pietanza MC

  • Hematol Oncol Clin North Am. 2016 Feb;30(1):83-102.

2016-02-17

Fig 1. Detailed structural schematic of a full-length IgG as well as an assortment of antibody fragments.

Fig 1. Detailed structural schematic of a full-length IgG as well as an assortment of antibody fragments.
  • Adumeau P, Sharma SK, Brent C, Zeglis BM

  • Mol Imaging Biol. 2016 Feb;18(1):1-17.

2016-02-18

Fig 1. Overview of the PI3K/AKT/mTOR pathway and cellular processes controlled by downstream signaling.

Fig 1. Overview of the PI3K/AKT/mTOR pathway and cellular processes controlled by downstream signaling.
  • Carmona FJ, Montemurro F, Kannan S, Rossi V, Verma C, Baselga J, Scaltriti M

  • Pharmacol Ther. 2016 Feb;158:63-70.

2016-02-19

Fig 4. PKLR promotes metastatic cell survival in the tumor core.

Fig 4. PKLR promotes metastatic cell survival in the tumor core.
  • Nguyen A, Loo JM, Mital R, Weinberg EM, Man FY, Zeng Z, Paty PB, Saltz L, Janjigian YY, de Stanchina E, Tavazoie SF

  • J Clin Invest. 2016 Feb 1;126(2):681-94.

2016-02-22

Fig 3. Radiation-induced cavernomas.

Fig 3. Radiation-induced cavernomas.
  • Stone JB, DeAngelis LM

  • Nat Rev Clin Oncol. 2016 Feb;13(2):92-105.

2016-02-23

Fig 3. Regulation of NK cell function and memory.

Fig 3. Regulation of NK cell function and memory.
  • Geiger TL, Sun JC

  • Curr Opin Immunol. 2016 Feb 1;39:82-89.
Open Access button

2016-02-24

Fig 1. Schematic of the hypothalamic-pituitary-gonadal axis and sites of action of antiandrogen therapies.

Fig 1. Schematic of the hypothalamic-pituitary-gonadal axis and sites of action of antiandrogen therapies.
  • Bhatia N, Santos M, Jones LW, Beckman JA, Penson DF, Morgans AK, Moslehi J

  • Circulation. 2016 Feb 2;133(5):537-41.

2016-02-25

Fig 1. The bed bug life cycle and developmental gene expression profile.

Fig 1. The bed bug life cycle and developmental gene expression profile.
  • Rosenfeld JA, Reeves D, Brugler MR, Narechania A, Simon S, Durrett R, Foox J, Shianna K, Schatz MC, Gandara J, Afshinnekoo E, Lam ET, Hastie AR, Chan S, Cao H, Saghbini M, Kentsis A, Planet PJ, Kholodovych V, Tessler M, Baker R, DeSalle R, Sorkin LN, Kolokotronis SO, Siddall ME, Amato G, Mason CE

  • Nat Commun. 2016 Feb 2;7:10164.

2016-02-26

Fig 4. Tyrosine kinase activation of nucleotide exchange modulates KRASG12C inhibition in cancer cells.

Fig 4. Tyrosine kinase activation of nucleotide exchange modulates KRASG12C inhibition in cancer cells.
  • Lito P, Solomon M, Li LS, Hansen R, Rosen N

  • Science. 2016 Feb;351(6273):604-608.

2016-02-29

Fig 1. Simplified schema of the coagulopathy associated with APL.

Fig 1. Simplified schema of the coagulopathy associated with APL.
  • Mantha S, Tallman MS, Soff GA

  • Curr Opin Hematol. 2016 Mar;23(2):121-6.

2016-03-01

Fig 1. Case 1.

Fig 1. Case 1.
  • Kanagal-Shamanna R, Xu-Monette ZY, Miranda RN, Dogan A, Zou D, Luthra R, Weber DM, O'Malley DP, Jorgensen JL, Khoury JD, Bueso-Ramos CE, Orlowski RZ, Medeiros LJ, Young KH

  • Histopathology. 2016 Mar;68(4):482-91.

2016-03-02

Fig 1. Telomere Length Associations in Glioma.

Fig 1. Telomere Length Associations in Glioma.
  • Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, Morozova O, Newton Y, Radenbaugh A, Pagnotta SM, Anjum S, Wang J, Manyam G, Zoppoli P, Ling S, Rao AA, Grifford M, Cherniack AD, Zhang H, Poisson L, Carlotti CG Jr, Tirapelli DP, Rao A, Mikkelsen T, Lau CC, Yung WK, Rabadan R, Huse J, Brat DJ, Lehman NL, Barnholtz-Sloan JS, Zheng S, Hess K, Rao G, Meyerson M, Beroukhim R, Cooper L, Akbani R, Wrensch M, Haussler D, Aldape KD, Laird PW, Gutmann DH; TCGA Research Network, Noushmehr H, Iavarone A, Verhaak RG

  • Cell. 2016 Jan 28;164(3):550-63.

2016-03-03

Fig 5. ER-independent exit from metabolic dormancy and HTR disease require IL6/Notch3 upregulation.

Fig 5. ER-independent exit from metabolic dormancy and HTR disease require IL6/Notch3 upregulation.
  • Sansone P, Ceccarelli C, Berishaj M, Chang Q, Rajasekhar VK, Perna F, Bowman RL, Vidone M, Daly L, Nnoli J, Santini D, Taffurelli M, Shih NNC, Feldman M, Mao JJ, Colameco C , Chen J, DeMichele A, Fabbri N, Healey JH, Cricca M, Gasparre G, Lyden D, Bonafé M, Bromberg J

  • Nature Communications. 2016 Feb 9;7:1-10.
Open Access button

2016-03-04

Fig 3. Pretreatment and intratreatment DCE MR images of a patient with locoregional control (63-year-old man).

Fig 3. Pretreatment and intratreatment DCE MR images of a patient with locoregional control (63-year-old man).
  • Jansen JF, Parra C, Lu Y, Shukla-Dave A

  • Magn Reson Imaging Clin N Am. 2016 Feb;24(1):123-33.

2016-03-07

Fig 4. Signaling pathways in thyroid cancer.

Fig 4. Signaling pathways in thyroid cancer.
  • Grewal RK, Ho A, Schöder H

  • Semin Nucl Med. 2016 Mar;46(2):109-18.

2016-03-08

Fig 1. Patterns of lymph node involvement by Merkel cell carcinoma.

Fig 1. Patterns of lymph node involvement by Merkel cell carcinoma.
  • Ko JS, Prieto VG, Elson PJ, Vilain RE, Pulitzer MP, Scolyer RA, Reynolds JP, Piliang MP, Ernstoff MS, Gastman BR, Billings SD

  • Mod Pathol. 2016 Feb;29(2):122-30.

2016-03-09

Fig 3. Waterfall plots presenting the ranking of individual patients according to the Response Evaluation Criteria in Solid Tumors response to treatment.

Fig 3. Waterfall plots presenting the ranking of individual patients according to the Response Evaluation Criteria in Solid Tumors response to treatment.
  • Konstantinidis IT, Groot Koerkamp B, Do RK, Gönen M, Fong Y, Allen PJ, D'Angelica MI, Kingham TP, DeMatteo RP, Klimstra DS, Kemeny NE, Jarnagin WR

  • Cancer. 2016 Mar 1;122(5):758-65.

2016-03-10

Fig 1. Model of acquisition of molecular genetic abnormalities in MDS, de novo AML, and CHIP.

Fig 1. Model of acquisition of molecular genetic abnormalities in MDS, de novo AML, and CHIP.
  • Chung SS

  • Curr Opin Hematol. 2016 Mar;23(2):79-87.

2016-03-11

Fig 1. TC structure and oncogenic effects in vitro.

Fig 1. TC structure and oncogenic effects in vitro.
  • Tanas MR, Ma S, Jadaan FO, Ng CK, Weigelt B, Reis-Filho JS, Rubin BP

  • Oncogene. 2016 Feb 18;35(7):929-38.

2016-03-14

Fig 2. Key Figure: Diverse Biological Roles of Alternative 3′ Untranslated Regions (3′UTRs).

Fig 2. Key Figure: Diverse Biological Roles of Alternative 3′ Untranslated Regions (3′UTRs).
  • Mayr C

  • Trends Cell Biol. 2016 Mar;26(3):227-37.

2016-03-15

Fig 1. An overview of class switching.

Fig 1. An overview of class switching.
  • DiMenna LJ, Chaudhuri J

  • Eur J Immunol. 2016 Mar;46(3):523-30.

2016-03-16

Fig 13. Illustrates a network visualization tool of altered gene nodes in the cBioPortal.

Fig 13. Illustrates a network visualization tool of altered gene nodes in the cBioPortal.
  • Sirintrapun SJ, Zehir A, Syed A, Gao J, Schultz N, Cheng DT

  • Clin Lab Med. 2016 Mar;36(1):153-81.

2016-03-17

Fig 3. Morphologic spectrum of EWSR1-ERG Ewing sarcomas.

Fig 3. Morphologic spectrum of EWSR1-ERG Ewing sarcomas.
  • Chen S, Deniz K, Sung YS, Zhang L, Dry S, Antonescu CR

  • Genes Chromosomes Cancer. 2016 Apr;55(4):340-9.

2016-03-18

Fig 4. MCT1 Loss-of-Function Reduces Breast Cancer Cell Proliferation and Tumor Growth.

Fig 4. MCT1 Loss-of-Function Reduces Breast Cancer Cell Proliferation and Tumor Growth.
  • Hong CS, Graham NA, Gu W, Espindola Camacho C, Mah V, Maresh EL, Alavi M, Bagryanova L, Krotee PA, Gardner BK, Behbahan IS, Horvath S, Chia D, Mellinghoff IK, Hurvitz SA, Dubinett SM, Critchlow SE, Kurdistani SK, Goodglick L, Braas D, Graeber TG, Christofk HR

  • Cell Rep. 2016 Feb 23;14(7):1590-601.
Open Access button

2016-03-21

Fig 5. Protein–protein interaction scheme generated from differentially regulated proteins upon HFD focused on lipid metabolism using STRING (version 10).

Fig 5. Protein–protein interaction scheme generated from differentially regulated proteins upon HFD focused on lipid metabolism using STRING (version 10).
  • Benard O, Lim J, Apontes P, Jing X, Angeletti RH, Chi Y

  • The Journal of Nutritional Biochemistry. 2016 May 31;31:10-9.

2016-03-22

Fig 1. Overview of HISs.

Fig 1. Overview of HISs.
  • Sirintrapun SJ, Artz DR

  • Clin Lab Med. 2016 Mar;36(1):133-52.

2016-03-23

Fig 1. PARP1 expression in human tongue tumors.

Fig 1. PARP1 expression in human tongue tumors.
  • Kossatz S, Brand C, Gutiontov S, Liu JT, Lee NY, Gönen M, Weber WA, Reiner T

  • Sci Rep. 2016 Feb 22;6:21371.
Open Access button

2016-03-24

Fig 1. Circos plot showing the chromosomal distribution of genes involved in recurrent and non-recurrent gene fusion in soft tissue tumors.

Fig 1. Circos plot showing the chromosomal distribution of genes involved in recurrent and non-recurrent gene fusion in soft tissue tumors.
  • Mertens F, Antonescu CR, Mitelman F

  • Genes Chromosomes Cancer. 2016 Apr;55(4):291-310.

2016-03-25

Fig 4. Comparison of Structures of Known ORC1 BAH Domains from Different Species.

Fig 4. Comparison of Structures of Known ORC1 BAH Domains from Different Species.
  • Li S, Yang Z, Du X, Liu R, Wilkinson AW, Gozani O, Jacobsen SE, Patel DJ, Du J

  • Structure. 2016 Mar 1;24(3):486-94.

2016-03-28

Fig 2. Time to response and duration of response.

Fig 2. Time to response and duration of response.
  • Antonia S, Goldberg SB, Balmanoukian A, Chaft JE, Sanborn RE, Gupta A, Narwal R, Steele K, Gu Y, Karakunnel JJ, Rizvi NA

  • Lancet Oncol. 2016 Mar;17(3):299-308.

2016-03-29

Fig 4. GEP and GSEA in primary testicular large B-cell lymphoma.

Fig 4. GEP and GSEA in primary testicular large B-cell lymphoma.
  • Deng L, Xu-Monette ZY, Loghavi S, Manyam GC, Xia Y, Visco C, Huh J, Zhang L, Zhai Q, Wang Y, Qiu L

  • Leukemia. 2016 Feb;30(2):361-72.

2016-03-30

Fig 4. Gain of function TP53 mutations and loss of TAp63 regulate key GPs associated with the squamous class.

Fig 4. Gain of function TP53 mutations and loss of TAp63 regulate key GPs associated with the squamous class.
  • Bailey P, Chang DK, Nones K, Johns AL, Patch AM, Gingras MC, Miller DK, Christ AN, Bruxner TJ, Quinn MC, Nourse C

  • Nature. 2016 Mar 3;531(7592):47-52.

2016-03-31

Fig 2. Summary of data.

Fig 2. Summary of data.
  • Reznik E, Miller M, Senbabaoglu Y, Riaz N, Lee W, Sander C

  • Elife. 2016 Feb 22;5. pii: e10769.
Open Access button

2016-04-01

Fig 2. Differentiation of human ES-cell-derived ENC precursors into enteric neuron subtypes.

Fig 2. Differentiation of human ES-cell-derived ENC precursors into enteric neuron subtypes.
  • Fattahi F, Steinbeck JA, Kriks S, Tchieu J, Zimmer B, Kishinevsky S, Zeltner N, Mica Y, El-Nachef W, Zhao H, de Stanchina E

  • Nature. 2016 Mar 3;531(7592):105-9.